Founded Year
2020Stage
Secondary Market | AliveTotal Raised
$7.3MExpert Collections containing AffyXell Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AffyXell Therapeutics is included in 1 Expert Collection, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Latest AffyXell Therapeutics News
Apr 14, 2022
Avacta Group announce that AffyXell Therapeutics has entered into a collaboration agreement with Biocytogen and the Korea Non-Clinical Technology Solution Center (KNTSC).
When was AffyXell Therapeutics founded?
AffyXell Therapeutics was founded in 2020.
What is AffyXell Therapeutics's latest funding round?
AffyXell Therapeutics's latest funding round is Secondary Market.
How much did AffyXell Therapeutics raise?
AffyXell Therapeutics raised a total of $7.3M.
Who are the investors of AffyXell Therapeutics?
Investors of AffyXell Therapeutics include Avacta, Shinhan Venture Investment, Shinhan Investment Corp., KOLON INVESTMENT, Gyeongnam Venture Investment and 6 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.